Lonza boosts ADC supply capacity through partnership expansion with unnamed major pharma
After a summer of commercial and team troubles, there’s some good news for Lonza as it extends its partnership with an unnamed “major biopharmaceutical partner” to enhance its antibody-drug conjugate manufacturing capabilities.
The extension builds on an existing collaboration between Lonza and the secret pharma company for end-to-end ADC manufacturing at Lonza’s Ibex Dedicate Biopark site in Visp, Switzerland. The deal covers payload and monoclonal antibody manufacturing as well as bioconjugation — the process whereby these two parts are covalently linked.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.